Could Medtronic’s Kanghui Purchase Set Course For US Entry?

Last month Medtronic agreed to pay close to $800 million for Chinese orthopedics implant maker China Kanghui Holdings. To be sure, the purchase of Kanghui secures Medtronic’s footing in China, one of the fastest growing health care economies in the world. In addition, it likely will help Medtronic close in on its goal of bringing in 20% of its revenue from emerging markets.

Since taking the CEO seat at Medtronic PLC last year, Omar Ishrak has set the multinational on two principal paths. The first path extends Medtronic’s reach into emerging markets, a popular destination for US and European health care companies seeking to tap into those countries’ surging economies to offset stagnant growth in their home markets. The second, less prominent, strategy is so-called reverse innovation, a philosophy Ishrak brought over from his time as CEO of GE HealthCare, the $12 billion subsidiary of General Electric. (SeeAlso see "Reverse Innovation: Is The US Losing Its Edge In Innovation?" - In Vivo, 24 January, 2012..) Historically, the US medical device industry has been rewarded for innovation that provides better clinical outcomes. But competing in emerging markets – and ultimately in developed markets – also might require device makers to produce tools that provide good-to-adequate outcomes at lower prices.

Medtronic brought both philosophies into play last month when it agreed to pay close to $800 million for Chinese orthopedics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

More from In Vivo

Rising leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

 
• By 

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.